Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Long-Term Debt Repayments (2020 - 2023)

Aptevo Therapeutics' Long-Term Debt Repayments history spans 4 years, with the latest figure at $3.5 million for Q1 2023.

  • For Q1 2023, Long-Term Debt Repayments fell 67.8% year-over-year to $3.5 million; the TTM value through Dec 2023 reached $3.5 million, down 71.74%, while the annual FY2023 figure was $3.5 million, 71.74% down from the prior year.
  • Long-Term Debt Repayments for Q1 2023 was $3.5 million at Aptevo Therapeutics, up from $500000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $22.1 million in Q1 2020 and bottomed at $500000.0 in Q2 2022.
  • The 4-year median for Long-Term Debt Repayments is $4.2 million (2021), against an average of $6.0 million.
  • The largest YoY upside for Long-Term Debt Repayments was 115.34% in 2022 against a maximum downside of 90.99% in 2022.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $22.1 million in 2020, then plummeted by 74.89% to $5.6 million in 2021, then plummeted by 90.99% to $500000.0 in 2022, then skyrocketed by 593.4% to $3.5 million in 2023.
  • Per Business Quant, the three most recent readings for APVO's Long-Term Debt Repayments are $3.5 million (Q1 2023), $500000.0 (Q4 2022), and $500000.0 (Q3 2022).